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P resentation of peptide Ags by MHC class II (MHC II) molecules to CD4
+ T cells is required for initiation and regulation of adaptive immune responses (1, 2) . The intracellular processes leading to peptide loading onto MHC II proteins have been characterized in some detail (3) . Newly synthesized MHC II assembles in the endoplasmic reticulum associated with invariant chain and is transported to Golgi apparatus for maturation and subsequently sorting to a specialized endosomal compartment for peptide loading (4) . In the MHC II loading compartment, the invariant chain is proteolyzed to leave the CLIP fragment occupying the peptide-binding groove (5) . Antigenic peptides resulting from proteolytic cleavage of exogenous and endogenous proteins are loaded to MHC II (6) . Removal of CLIP from MHC II and loading of antigenic peptides to MHC II are catalyzed by DM (HLA-DM in humans and H2-M in mice) (7) (8) (9) (10) . Peptide-loaded MHC II molecules are transported to the cell surface for presentation to CD4 + T cells and stimulation of an immune response. MHC II recycled from the cell surface can exchange peptide by a similar process (11) .
DM plays a key role in MHC II Ag presentation and CD4 + T cell epitope selection (12) (13) (14) (15) (16) (17) . DM is considered a nonclassical MHC II because it is not highly polymorphic and does not have peptidebinding capacity (18) (19) (20) (21) (22) . Instead, DM acts as a peptide editor to catalyze the exchange of CLIP and other peptides onto MHC II during Ag presentation (8) (9) (10) . We and other researchers have shown that DM-mediated peptide exchange plays a key role in epitope selection by favoring the presentation of peptides with higher kinetic stability (12, 15-17, 23, 24) . DM deficiency results in predominant accumulation of MHC II-CLIP complexes at the cell surface and defective peptide loading and exchange, leading to defective negative selection, increased self-reactivity, and immunodeficiency (25) (26) (27) . DM has been shown to promote both peptide binding and release for peptides of varied sequences in vitro, with the combined effect accounting for facilitated peptide exchange (7, 28) .
During the last two decades, much effort has been devoted to elucidation of the mechanism of DM-catalyzed peptide release (18, 21, (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) . DM binds MHC II near the N terminus of the peptidebinding groove and disrupts peptide binding by inducing or stabilizing a conformation with altered a subunit 3 10 helix and adjacent extended strand (21, 28, 36) . The region with altered structure is involved in key MHC II-peptide interactions (21, 32, 35) . MHC II-peptide complexes appear to be highly dynamic and adopt various conformations (40, 41) . Recently, we and others proposed a model that DM catalyzes peptide release by sensing the dynamic conformation of MHC II-peptide complex constrained by the interactions throughout peptide-binding groove (42) , and by recognizing a conformation involving the rearrangement of MHC II a 3 10 helical and extended region near the Nterminal side of bound peptide in the vicinity of P1 pocket (21) .
In contrast to dissociation of bound peptide from MHC II, loading of peptides to MHC II is more complex owing to multiple steps and various intermediate species involved in the binding process (43) (44) (45) (46) . As a result, understanding of the mechanism of DM-catalyzed peptide association is still limited. It has been demonstrated that MHC II undergoes a reversible isomerization between active peptide-receptive and inactive peptide-averse conformations (44, 45) . Also proposed is a transient species formed between peptide and MHC II that finally resolves into stable MHC II-peptide complex (43) . In different studies, DM has been proposed to catalyze peptide association through different mechanisms. According to one model, DM acts as a molecular chaperone to stabilize empty MHC II against inactivation and aggregation to facilitate peptide loading (47, 48) . In another, DM interacts only with MHC II-peptide complex, not empty MHC II, and promotes transition between transient and stable MHC IIpeptide complex (49) . It has also been suggested that DM catalyzes peptide loading by specifically recognizing unstable conformations of MHC II-peptide complexes and actively converting them into active peptide-receptive MHC II (46) . More recently, Grotenbreg et al. (50) proposed a model wherein DM contributes directly to peptide association through formation of a peptideloading complex between DM and empty MHC II. Resolution of this issue requires expression of each model in a testable way and design of experiments that could distinguish each model.
In this study, we tracked real-time peptide association kinetics under various experimental conditions using a fluorescence polarization (FP) assay and evaluated several potential kinetic mechanisms for the role of DM in facilitating peptide association. Our data suggest that DM does not stabilize MHC II against aggregation or promote transition of peptide-averse to peptidereceptive conformation. Instead, the experimental data fit with a model wherein DM forms an intermediate with MHC II that binds peptide with faster kinetics but also resolves more quickly into inactive MHC II in the absence of peptides.
Materials and Methods

Peptide synthesis and labeling
For peptide-binding assays, N-terminally acetylated influenza hemagglutinin (306-318)-derived HA analog (Ac-PRFVKQNTLRLAT) and CLIP peptide (Ac-VSKMRMATPLLMQ) were synthesized (21st Century Biochemicals, Marlboro, MA) and labeled with Alexa Fluor 488 tetrafluorophenyl ester (Invitrogen, Eugene, OR) through primary amine of K 5 (HA) and K 3 (CLIP). For MHC II stabilization assay, MHC class I HLA-A2 (104-117)-derived W1A peptide (Ac-GSDARFLRGYHQYA) and HA peptide (Ac-PKYVKQNTLKLAT) were synthesized with acetylated N termini.
Protein expression and purification
Soluble extracellular domains of recombinant HLA-DR1 (DR1) (DRA*0101/ DRB1*010101) and DM were expressed in Drosophila S2 cells and purified by immunoaffinity chromatography followed by Superdex200 (GE Healthcare) size exclusion chromatography as described (7, 51) . Full-length native DR1 from LG2 lymphoblastoid cells were solubilized using octyl glucoside detergent and isolated by immunoaffinity chromatography as described (52) .
Peptide occupancy
To evaluate peptide occupancy, samples of DR1, DM, DR1 preloaded with HA peptide, and full-length DR1 carrying a spectrum of naturally processed peptides were acid denatured for 1 h at room temperature with trifluoroacetic acid (final pH, ∼1.5-2) and characterized by MALDI mass spectrometry. Mass spectra were obtained using a Micromass MALDI-LR instrument (Waters, Milford, MA). Samples (∼4.8 pmol for DR1 and DM, and ∼1.0 pmol for DR1 preloaded with HA and DR1 from LG2) and matrix (a-cyano-4-hydroxycinnamic acid, Sigma-Aldrich, St. Louis, MO) were loaded onto the plate and data were acquired in reflectron mode and analyzed using MassLynx software v4.0 (Waters). For characterization by quantitative amino acid analysis, 2.7-mg samples were denatured in 1 ml 1% trifluoracetic acid for 1 h at room temperature, followed by centrifical ultrafiltration in Centricon-10 devices (10 kDa molecular mass cutoff) with filtrate collection and lyophilization. Amino acid analysis was performed by 21st Century Biochemicals.
FP assay
FP assay was used to measure real-time peptide association kinetics as described previously (53) . Briefly, 25 nM Alexa Fluor 488-labeled HA or CLIP was mixed with various concentrations of DR1 (ranging from 0.1 to 1.6 mM) in the presence of different DM concentrations (ranging from 0 to 1.6 mM) in 200 ml pH 5.5 binding buffer (100 mM sodium citrate, 50 mM NaCl, 0.1% octylglucoside, 5 mM EDTA, 0.1% NaN 3 , 1 mM DTT, 13 protease inhibitor mixture) in 96-well nonbinding black polystyrene plates (Corning, Corning, NY). Real-time peptide binding was monitored by FP using Victor X5 Multilabel plate reader (PerkinElmer, Shelton, CT) at 488 nm excitation and 520 nm emission. Numerical modeling of peptide-binding reactions DM-catalyzed peptide association reactions to MHC II were simulated with KinTek Explorer (39, 54, 55) . KinTek Explorer simulates binding reactions by direct numerical integration of coupled rate equations and fits with experimental data to yield estimates for rate constants of microscopic kinetic steps, which has been widely used to determine the kinetic mechanism of enzymatic reactions (54) (55) (56) (57) (58) (59) (60) . The model described in scheme V was used to simulate peptide association kinetics and fit with experimental data.
Results
DM catalyzes peptide association to MHC II
We used a FP-based assay to track real-time peptide association kinetics to peptide-free DR1 produced in S2 insect cells. Many recombinant MHC II proteins produced in insect cells previously have been reported to be suitable for in vitro peptide-binding experiments, including DR1, DR2b, DR3, DR4, DR52, DR2a, and DQ (17, 31, 35, 61) . Among these proteins, DR1 produced in baculovirus-infected Sf9 insect cells cultured in serum-free media in particular appears to be substantially free of associated peptide, as demonstrated by sensitivity to SDS-induced denaturation, increased peptide-binding rate and capacity, decreased pH dependence of peptide binding, and, most directly, by the absence of associated peptides as quantitated by amino acid analysis (62) .
To verify that DR1 produced in S2 insect cells was substantially free of associated peptide, we performed quantitative amino acid analysis of acid-eluted material from three samples of DR1 isolated from S2 cells, as originally described for DR1 isolated from baculovirus-infected Sf9 insect cells (62) . No significant amino acid content was observed in these samples (1.02, 1.99, and 3.45 nmol amino acid per 50 nmol protein) relative to that present in a control DM sample (3.46 nmol per 50 nmol protein). Amino acid analysis for DR1 preloaded with HA revealed expected stoichiometry (data not shown). Additionally, we examined DR1 acid elutes by MALDI mass spectrometry ( Fig. 1 ). Ions corresponding to peptidic material were not observed in samples of DR1 or peptide-free DM produced in S2 insect cells (Fig. 1A, 1B) , whereas peptides were readily observed for DR1 preloaded with HA peptide (Fig. 1C ) or for native DR1 isolated from LG2 lymphoblastoid cells (Fig. 1D ). To evaluate the effect of DM on the overall association reaction, we followed CLIP peptide binding to various concentrations of DR1 by the FP assay in the presence of various concentrations of DM ( Fig. 2A-F) . We observed in each case that DR1 peptide binding proceeded faster in the presence of DM ( Fig. 2A-F) . Within each set of curves, the rate increase depended on the dose of DM. For each curve, we calculated the initial rate of peptide binding (the slope of a linear fit to the early part of each association curve) and plotted these against the concentration of DM (Fig. 2G ) or DR1 (Fig. 2H) . The initial rate of peptide binding increases with the concentration of DM (Fig. 2G) . The initial rate of peptide binding increases with DR1 concentration up to a point but then saturates (Fig. 2H) , which is an expected behavior for a classic enzyme substrate system as previously observed for DMcatalyzed peptide binding to MHC II (7, 28, 29) .
Evaluation of models for the role of DM in MHC II-peptide association
We sought to evaluate different kinetic mechanisms for DMfacilitated peptide association. A reversible isomerization between active peptide-receptive conformation of empty MHC II (MHCa) and inactive peptide-averse conformation of MHC II (MHCi) has been repeatedly observed during intrinsic or DM-catalyzed peptide association (43) (44) (45) (47) (48) (49) (50) . In our evaluation of possible mechanisms for DM-catalyzed peptide association, we always included a step corresponding to transition between MHCa and MHCi. In an earlier study of the noncatalyzed association reaction, we observed saturation of the initial peptide-binding rate with increasing peptide or MHC concentration (43) . This was explained by a unimolecular conformational change between transient and stable conformations after the initial bimolecular binding (43, 46, 49, 63, 64) . We therefore also included in all models conversion of a transient unstable MHC II-peptide complex (MHCpep9) to a stable MHC IIpeptide complex. Other aspects of the overall association reaction differ between the various models, and these are discussed individually below.
DM does not facilitate peptide binding by stabilizing MHC II against aggregation
A previous study has indicated that preincubation of DR1 alone leads to the aggregation and functional inactivation of DR1, and preincubation of DR1 and DM together could rescue the activity of DR1 (48) . We first evaluated whether DM facilitates peptide binding by stabilizing empty MHC II against aggregation. We incubated purified DR1 monomer alone, with DM, or with peptide, in each case at 37˚C overnight in buffer with endosomal pH. If DM were able to stabilize DR1 in this manner, we would expect to see that incubation of DR1 alone leads to the aggregation of DR1, whereas incubation of DR1 together with DM would prevent the aggregation of DR1. Before incubation, both purified nonpeptide-loaded DR1 and preloaded DR1-HA eluted as single monomer peaks (Fig. 3A) . As previously observed, the elution times of these species differ, with the peptide-bound complex adopting a compact conformation and the empty protein adopting a more open conformation (65) . Consistent with previous studies (62, 66, 67) , empty MHC II aggregated during the incubation period (Fig. 3B, red curve) . Inclusion of HA peptide in the incubation mixture stabilized MHC II such that aggregation was not observed (Fig. 3B , blue curve). The extent of aggregation level was similar with DM included in the incubation mixture (Fig. 3B , green curve). The same phenomenon was observed when the incubation time at 37˚C was reduced from overnight to 1 h (data not shown). Thus, we did not observe that DM could directly stabilize MHC II against aggregation. To validate this observation, we loaded DR1 with the weakly binding peptide W1A, which we identified recently as extremely susceptible to DM-mediated peptide release (42) , and incubated this complex alone or in the presence of DM or peptide (Fig. 3C) . This experiment is similar to the previous one, but with the empty protein generated in situ by release of a weakly bound peptide instead of starting with the non-peptide-loaded protein. Consistently, incubation of DR1-W1A at 37˚C for 1 h in buffer with endosomal pH resulted in the aggregation of MHC II (Fig. 3C, red curve) . Excess of peptides but not DM could inhibit the aggregation of MHC II (Fig. 3C,  green and blue curves) . Therefore, we conclude that DM has no direct effect of stabilizing MHC II against aggregation. We tested whether aggregated MHC II exhibits slower peptide-binding kinetics than monomeric MHC II. Surprisingly, aggregated DR1 bound to Alexa Fluor 488-HA equally well, if not better, compared with monomeric DR1 (Supplemental Fig. 1 
DM does not facilitate peptide binding by converting inactive MHC II to active form
MHC II undergoes reversible isomerization between peptidereceptive and peptide-averse states (44, 45) , and up to .90% of MHC II prepared as a recombinant protein can be in the inactive peptide-averse form at equilibrium (43, 44) . We evaluated a model wherein DM catalyzes peptide association by promoting the transition of inactive MHC II to active form. We considered four possible mechanisms by which DM could mediate conversion of inactive MHC II to an active form, as shown by schemes I-IV (Fig. 4) . In scheme I, DM acts as a molecular chaperone for MHCa and prevents the inactivation of MHCa by preserving MHC II in the active form. During peptide binding, MHCa is released from the intermediate with DM and binds peptide. In scheme II, DM binds to MHCi to promote transition of MHCi to MHCa. In scheme III, DM directly interacts with MHCi, forming an intermediate DM-MHC that allows peptide binding to MHCi. In scheme IV, DM interacts with MHCa as a molecular chaperone by competing with inactivation and forming an intermediate DM-MHC that binds peptide with a faster rate. To test schemes I-IV, we tracked the binding kinetics of HA and CLIP peptides to DR1 in the absence of DM, in the presence of DM, or in the presence of DM that had been preincubated together with DR1. Our rationale is that if DM catalyzes peptide association by converting inactive MHC II to active form, preincubation of DR1 with DM would largely increase the initial rate of peptide binding due to increased amount of peptide-receptive MHC II. To control for effects of the incubation period on DM activity, we separately preincubated DM before adding it to preincubated DR. All these samples were incubated at 37˚C in pH 5.5 buffer overnight before adding Alexa Fluor 488-labeled peptides for binding. We observed faster HA binding to DR1 in the presence of DM, both for DM incubated separately and for DM preincubated with DR1 ( Fig. 5A-C) . Surprisingly, preincubation of DR1 with DM decreased initial HA binding compared with adding DM separately (Fig. 5A-C) , although they reached the same overall binding level (Fig. 5D-F) . The initial rate of binding was 20% lower and significantly different when preincubating DM with DR1 compared with adding DM separately (Fig. 5G) . The same experiments were performed for CLIP, which showed the essentially same behavior (Fig. 6) . Thus, DM does not convert inactive MHC II to active form.
We sought to understand why preincubation of DM and MHC II together led to slower binding than the same reaction where DM and MHC II were preincubated separately. A possibility is that interaction of DM with MHC II in the absence of peptides actually results in inactivation of MHC II. To test the hypothesis that interaction of DM with MHC II in the absence of peptides leads to inactivation not activation of MHC II, we did a time course of preincubation of DR1 with DM and tracked the catalytic effect on HA association (Fig. 7A-F) . The initial rate in each condition was plotted (Fig. 7G) . We observed that incubation of DR1 alone in the absence of peptide resulted in intrinsic functional inactivation (Fig. 7G, green curve) . This intrinsic inactivation was also observed in conditions where DR1 and DM were incubated separately followed by peptide binding as shown by the parallel curves for incubation of DR1 alone (Fig. 7G , green curve) and DR1 separately with DM (Fig. 7G, blue curve) . However, preincubation of DR1 together with DM leads to facilitated inactivation of DR1, with differences evident at 2 h and statistically substantial at 6 h of incubation (Fig. 7G, red curve) (28, 47, 50, 69) . By taking into account the inactivation of MHC II in the absence of peptides and its facilitation by DM (Figs. 5-7) , we developed a model that can explain both the observed facilitated peptide binding and also increased inactivation. In this model (scheme V) DM catalyzes peptide association by forming an intermediate with MHC II, which binds peptides with faster kinetics but resolves into inactive MHC II in the absence of peptides (Fig. 4) . In the presence of peptides, the transient intermediate DM-MHC binds peptide with faster kinetics as in scheme IV. In the absence of peptides, DM-MHC resolves into MHCi to facilitate inactivation.
To test scheme V, we mathematically simulated the binding reactions and fit experimental real-time peptide binding kinetic data to the simulated model, using KinTek Explorer software. Peptide-binding reactions described in scheme V were simulated for HA and CLIP binding to DR1 in the absence of DM, in the presence of preincubated DR1 and DM, and in the presence of separately incubated DM, in each case using the 0.4 mM DR1 data in Figs. 5 and 6. The experimental data and computation simulation fits are shown in Fig. 8 with the experimental setup listed in Supplemental Table I . The model in schemes II-IV could not fit the experimental data because it cannot account for the inactivation of DM-interacting MHC II in the absence of peptides (data not shown). We equilibrated the system for 1000 min during the preincubation step with or without DM to simulate overnight incubation (Supplemental Table I ). The values of k-4 and k-5 were set to 0, because in the model DM only interacts with active MHC II and DM-MHC II complex resolves into inactive MHC II in the absence of peptides as discussed above. The initial starting values for other rate constants were set based on previous literature on MHC II interacting with DM or HA and CLIP peptides (28, 43, 49, 50) (Supplemental Table II) . Values for k1, k-1, k4, k-4, k5, and k-5 were kept the same for HA and CLIP, whereas other rate constants were fitted separately for each peptide. The value for k5 was not previously estimated because to our knowledge, it is first developed in the present study. The values for k2 CLIP , k-2 CLIP , k-3 CLIP , k6 CLIP , k7 CLIP , and k-7 CLIP have not been previously evaluated experimentally, and they were obtained by curve fitting as described below.
Fitting the model in scheme V to experimental data yields excellent fits (Fig. 8) . The best fit parameter values are listed in Table I . We found that the fraction of active MHC II preset in the beginning of simulation did not change the data fitting because it was equilibrated out during the preincubation. Multiple combinations of k2 and k3 and of k6 and k7 (i.e., k2 CLIP = 0. Each sample has three replicates. The two-tailed p value of unpaired t test for the comparison between DR1 preincubated with DM (red curve) and adding DM together with peptides (blue curve) is shown in (G). The p value for the initial rate versus incubation curve fitted to a onephase decay is also shown for those two groups. Nonsignificant p value is not shown. *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001. duce the same fits, which corresponds to the long intrinsic and DMcatalyzed dissociation half-life (∼100 h) for HA compared with short half-life for CLIP (∼5 h) as previously reported (7, 8, 17, 28-31, 33, 34, 37, 43, 49, 70) . Notably, k4 must be .1 mM 21 min
21
, and coupled rate of k6 and k7 must be at least 15-fold greater than coupled rate of k2 and k3 to capture the fast DM-catalyzed peptide association, which indicated that DM forms an intermediate with active MHC II-binding peptides in a faster kinetics. Importantly, k5 must be larger than k-1 to capture the facilitated inactivation when incubating DR1 together with DM in the absence of peptides. In summary, we have demonstrated that a model that DM facilitates both peptide binding and MHC II inactivation fits with the experimental data.
Discussion
The mechanism of DM-facilitated MHC II-peptide exchange is a fundamental problem in Ag presentation. Substantial effort has been devoted to understanding DM-catalyzed peptide dissociation (71, 72) , but DM-catalyzed peptide association is not well understood mechanistically (46) (47) (48) (49) (50) . In this study, we systematically evaluated several potential kinetic mechanisms by which DM could catalyze peptide loading. We tracked real-time peptide association kinetics under a wide range of conditions designed to test various kinetic models, and we mathematically simulated peptide-binding reactions and fit these to experimental data. Our data demonstrate that DM does not promote peptide loading by stabilizing MHC II against aggregation or by converting inactive MHC II to active forms. Instead, the experimental data are consistent with a model in which DM facilitates peptide loading by forming an intermediate with an active form of MHC II, with the DM-MHC II complex binding peptides with faster kinetics but resolving into inactive MHC II in the absence of peptides.
Several models have been proposed previously to explain DM-facilitated peptide loading (43) (44) (45) (46) (47) (48) (49) (50) . Most reports agree on a reversible isomerization between active peptide-receptive and inactive peptide-averse MHC II conformations. However, discrepancy exists on whether DM facilitates peptide loading by preventing inactivation (or aggregation) of MHC II (47, 48, 50) , or by converting inactive MHC II to active forms (46) , or by forming an intermediate with MHC II (50), and whether DM interacts with both non-peptide-loaded and peptide-loaded MHC II (47, 48, 50) or only with peptide-loaded MHC II (49) . DM has been reported to stabilize MHC II against inactivation assayed by enhanced peptide binding in the presence of DM (47, 48, 50) . We did not observe a direct effect of DM on preventing MHC II aggregation. It is possible that the stabilization observed previously is due to the secondary effect of peptide binding, with DM preventing MHC II inactivation indirectly by promoting productive peptide binding. Evidence for this came from the observation that peptide but not DM can prevent MHC II aggregation. An earlier study proposing that DM catalyzes peptide association by converting inactive MHC II to active forms was evidenced by the fact that preincubation of DR1 with DM enhanced peptide binding compared with intrinsic peptide binding (48) . This phenomenon was also observed in our study. However, in that study, no comparison between preincubating DR1 with DM in the absence of peptides and adding DM together with peptides was made (48) , and it is possible that the observed stabilization was indirect. The enhanced peptide binding that we observed for preincubated DR1 and DM be may due to DM forming an intermediate with MHC II that FIGURE 8 . Mathematical modeling of peptide association reactions in scheme V and fitting with experimental data. Peptide-binding reactions described in scheme V were simulated and data fitting was done with KinTek Explorer under three conditions (Supplemental Table I ): non-peptide-loaded DR1 was incubated alone for 1000 min (mixing step 1), and Alexa Fluor 488-labeled HA was added to track real-time binding for 1000 min (mixing step 2); nonpeptide-loaded DR1 was incubated together with DM (mixing step 1) and Alexa Fluor 488-labeled HA was added to track real-time binding (mixing step 2); non-peptide-loaded DR1 was incubated separately (mixing step 1), and Alexa Fluor 488-labeled HA and DM were added to track real-time binding (mixing step 2). Experimental data and simulated values were shown for (A) HA association and (B) CLIP association. The final concentration of total DR1, DM, and Alexa Fluor 488-labeled peptide was 0.4, 0.4, and 0.025 mM, respectively. binds peptide in a faster kinetics, as proposed in a recent study (50) . In that study the authors also proposed that DM binds MHC II to stabilize it from unfolding and aggregating (50 A key aspect of the model proposed in this study for DMcatalyzed peptide loading is that DM forms an intermediate with active MHC II, which resolves into inactive conformation in the absence of peptides but can bind peptides in a faster kinetics. This model is consistent with recent structural characterizations. In a structure proposed for the peptide-averse form of empty MHC II based on molecular dynamics simulations, the a subunit extended strand region occupies the N-terminal side of the peptide-binding groove to inhibit peptide binding (40) . Recent crystal structures of DM-DR (21) and DM-DO (22) complexes show that DM acts to catalyze peptide release by inducing (or stabilizing) conformational changes in the a subunit extended strand region that destabilize peptide-MHC interactions at the N-terminal side of the peptide-binding groove. Were DM to interact with non-peptideloaded MHC II in the same manner as observed in the DM-DR and DM-DO crystal structures, it would have the effect of promoting conversion between active peptide-receptive and inactive peptide-averse forms as observed in the kinetic studies reported in the present study.
The major conclusion of this work is that DM promotes peptide binding by forming an intermediate with MHC II that binds peptides with faster kinetics compared with MHC II alone. Efficient loading of antigenic peptides to MHC II is required for the initiation and regulation of adaptive immune responses (73) . In response to a variety of stimuli, professional APCs, such as dendritic cells, transform from an immature state specialized for protein Ag uptake into a mature state specialized for presentation of antigenic peptides for T cell activation (74) . Dendritic cell maturation is accompanied by enhanced lysosomal acidification, which results in increased Ag proteolysis (74, 75) . The proteolytic activity is tightly controlled in APCs to prevent complete destruction of protein Ags and to ensure efficient presentation of immunodominant epitopes (74, 76) . DM resides in endosomal peptideloading compartments together with MHC II (10, 47, 77) . By forming an intermediate with MHC II that binds peptides in a faster kinetics, DM could efficiently facilitate peptide loading during infection to initiate adaptive immunity. This idea is supported by the observation that cells from DM-deficient mice poorly present both whole proteins and short peptides (26, 27) . The mechanism we describe for DM-catalyzed peptide association also involves facilitated MHC II inactivation in the absence of peptides (scheme V). Although this phenomenon happens in the physiological time frame of MHC II and DM residence half-life in peptide loading compartment (78, 79) , the physiological relevance is still unknown because conditions under which there are absence or limited amount of peptides are not well illustrated.
In summary, by tracking real-time peptide association kinetics, mathematically modeling peptide binding reactions, and fitting with experimental data, we systematically established that DM catalyzes peptide loading by forming an intermediate with MHC II that binds peptides with faster kinetics but resolves into inactive MHC II in the absence of peptides. Our study provides novel insight into how DM efficiently catalyzes antigenic peptides loading during Ag presentation. a Mixing steps, species involved in the reactions, dilution factor, time of observation, and observables were listed in the experiment set up (Ex. Set up).
b Dilution factor in Mixing step 2 means species in Mixing step 1 were diluted by that factor to be considered in the final reaction.
c Observable is the FP value of sample as measured by FP assay. The constant a in Observable is the FP value for Alexa488-labeled peptide in complex with MHC II, and it was experimentally determined as 316 for DR1-Alexa488HA and 160 for DR1-Alexa488CLIP; the constant b in Observable is the FP value for unbound Alexa488-labeled HA or CLIP and it was experimentally determined as 32 for Alexa488HA and 28 for Alexa488CLIP. Experimental data of FP were fitted to the simulated data for FP of each sample (Observable). 
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